A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Momelotinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 20 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
- 22 Oct 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2016.